Apricoxib (BioDeep_00000177000)

   

human metabolite blood metabolite


代谢物信息卡片


4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzene-1-sulphonamide

化学式: C19H20N2O3S (356.119457)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 92.31%

分子结构信息

SMILES: CCOC1=CC=C(C=C1)C1=CC(C)=CN1C1=CC=C(C=C1)S(N)(=O)=O
InChI: InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)

描述信息

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C80509 - COX-2 Inhibitor
C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor

同义名列表

6 个代谢物同义名

4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzene-1-sulphonamide; 4-[2-(4-ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzene-1-sulfonamide; 2-(4-Ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1H-pyrrole; R-109339CS-706TG01; CS706 CPD; Apricoxib



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Martin J Edelman, Ming T Tan, Mary J Fidler, Rachel E Sanborn, Greg Otterson, Lecia V Sequist, Tracey L Evans, Bryan J Schneider, Roger Keresztes, John S Rogers, Jorge Antunez de Mayolo, Josephine Feliciano, Yang Yang, Michelle Medeiros, Sara L Zaknoen. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan; 33(2):189-94. doi: 10.1200/jco.2014.55.5789. [PMID: 25452446]
  • Barbara J Gitlitz, Eric Bernstein, Edgardo S Santos, Greg A Otterson, Ginger Milne, Mary Syto, Francis Burrows, Sara Zaknoen. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Apr; 9(4):577-82. doi: 10.1097/jto.0000000000000082. [PMID: 24736085]
  • Karen Reckamp, Barbara Gitlitz, Lin-Chi Chen, Ravi Patel, Ginger Milne, Mary Syto, Deborah Jezior, Sara Zaknoen. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer. 2011 Feb; 117(4):809-18. doi: 10.1002/cncr.25473. [PMID: 20922800]
  • Shashank Rohatagi, Helen Kastrissios, Kunihiro Sasahara, Kenneth Truitt, James B Moberly, Russell Wada, Daniel E Salazar. Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain. British journal of clinical pharmacology. 2008 Jul; 66(1):60-70. doi: 10.1111/j.1365-2125.2008.03175.x. [PMID: 18522627]
  • S Rohatagi, H Kastrissios, Y Gao, N Zhang, J Xu, J Moberly, R Wada, K Yoshihara, M Takahashi, K Truitt, D Salazar. Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor. Journal of clinical pharmacology. 2007 Mar; 47(3):358-70. doi: 10.1177/0091270006296152. [PMID: 17322148]